|
|
||||||||
1Divisions of Cardiac and Vascular and Basic Medical Sciences, St. George's, University of London, London; 2School of Human and Life Sciences, Whitelands College, Roehampton University, London; and 3Department of Cystic Fibrosis, Royal Brompton Hospital, London, United Kingdom
Submitted 15 December 2006 ; accepted in final form 12 February 2007
In animals, glucose concentrations are 3–20 times lower in lung lining fluid than in plasma. In humans, glucose concentrations are normally low (<1 mmol/l) in nasal and bronchial fluid, but they are elevated by inflammation or hyperglycemia. Furthermore, elevated bronchial glucose is associated with increased respiratory infection in intensive care patients. Our aims were to estimate normal glucose concentrations in fluid from distal human lung sampled noninvasively and to determine effects of hyperglycemia and lung disease on lung glucose concentrations. Respiratory fluid was sampled as exhaled breath condensate, and glucose was measured by chromatography with pulsed amperometric detection. Dilution corrections, based on conductivity, were applied to estimate respiratory fluid glucose concentrations (breath glucose). We found that breath glucose in healthy volunteers was 0.40 mmol/l (SD 0.24), reproducible, and unaffected by changes in salivary glucose. Breath-to-blood glucose ratio (BBGR) was 0.08 (SD 0.05). Breath glucose increased during experimental hyperglycemia (P < 0.05) and was elevated in diabetic patients without lung disease [1.20 mmol/l (SD 0.69)] in proportion to hyperglycemia [BBGR 0.09 (SD 0.06)]. Breath glucose was elevated more than expected for blood glucose in cystic fibrosis patients [breath 2.04 mmol/l (SD 1.14), BBGR 0.29 (SD 0.17)] and in cystic fibrosis-related diabetes [breath 4.00 mmol/l (SD 2.07), BBGR 0.54 (0.28); P < 0.0001]. These data indicate that 1) this method makes a biologically plausible estimate of respiratory fluid glucose concentration, 2) respiratory fluid glucose concentrations are elevated by hyperglycemia and lung disease, and 3) effects of hyperglycemia and lung disease can be distinguished using the BBGR. This method will support future in vivo investigation of the cause and effect of elevated respiratory fluid glucose in human lung disease.
exhaled breath condensate; diabetes mellitus; hyperglycemic clamp
This article has been cited by other articles:
![]() |
M. Moscoso and E. Garcia Transcriptional Regulation of the Capsular Polysaccharide Biosynthesis Locus of Streptococcus Pneumoniae: a Bioinformatic Analysis DNA Res, June 1, 2009; 16(3): 177 - 186. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. P. R. Rosias, Q. Jobsis, K. van de Kant, C. Robroeks, C. P. van Schayck, L. J. I. Zimmermann, and E. Dompeling Global condensation: a "climate change" towards better standardisation of exhaled breath condensate measurements Eur. Respir. J., March 1, 2008; 31(3): 684 - 685. [Full Text] [PDF] |
||||
![]() |
G. E. Kaufman and J. Yother CcpA-Dependent and -Independent Control of Beta-Galactosidase Expression in Streptococcus pneumoniae Occurs via Regulation of an Upstream Phosphotransferase System-Encoding Operon J. Bacteriol., July 15, 2007; 189(14): 5183 - 5192. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Visit Other APS Journals Online |